-+ 0.00%
-+ 0.00%
-+ 0.00%

Lianhuan Pharmaceutical (600513.SH) subsidiary obtained dapagliflozin metformin sustained-release tablet drug registration certificate

Zhitongcaijing·07/16/2026 08:33:08
Listen to the news

Zhitong Finance App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Xinxiang Changle Pharmaceutical Co., Ltd., the holding subsidiary of the company, recently received the “Drug Registration Certificate” for dagliflozin metformin sustained-release tablets (I/II/III) approved and issued by the State Drug Administration. Dapagliflozin metformin extended-release tablets (I/II/III) are suitable for improving blood sugar control in adult patients with type 2 diabetes receiving dapagliflozin and metformin hydrochloride in combination with diet control and exercise. The drug is declared according to the 4 categories of chemicals, and is deemed to have passed the consistent evaluation of the quality and efficacy of generic drugs.